Novo Nordisk strikes deal worth up to $1.1 billion to expand cardio business

Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros to strengthen its cardiovascular pipeline.

A view of the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros to strengthen its cardiovascular pipeline. "By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programmes across all phases of clinical development," Novo said in a statement.

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Novo Nordisk market cap surpasses Tesla on new obesity pill trial dataWegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results for its new experimental weight loss pill.
مصدر: CNBC - 🏆 12. / 72 اقرأ أكثر »